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Background. No reliable tests or validated biomarkers exist to ensure parasitological cure following treatment of Chagas disease 
(CD) patients chronically infected with Trypanosoma cruzi. As seroreversion, the only marker of cure, happens more quickly in chil-
dren, we investigated the correlation between previously identified biomarkers and seroreversion in children.
Methods. Thirty CD children (age 1 month to 10 years) diagnosed as T. cruzi positive (time point S0) were treated with ben-
znidazole (BZ) 5–8 mg/kg/d for 60 days. At least 2 serological tests were used to evaluate treatment efficacy from the end of treat-
ment (S1) until seroreversion (S2). Thirty children (age 1 month to 10 years) and 15 adults were used as healthy controls (HCs). 
Immunoblot and a proteomic-based assay were used to validate previously identified fragments of apolipoprotein A-1 (ApoA1) and 
fibronectin (FBN) as CD biomarkers.
Results. Correlation between seroreversion and absence of ApoA1 and FBN fragments by immunoblot was observed in 30/30 
(100%) and 29/30 (96.6%) CD children, respectively. ApoA1 and FBN fragments were absent at the end of BZ treatment in 20/30 
(66.6%) and 16/30 (53.3%) children, respectively. Absence of fragments in serum profiles was confirmed by mass spectrometry. 
Using intact protein analysis, a 28 109-Da protein identified as full-length ApoA1 by tandem mass spectrometry was detected in HC 
serum samples.
Conclusions. These data confirm that ApoA1 and FBN fragments can discriminate between healthy and T. cruzi–infected sam-
ples. Correlation with seroreversion was shown for the first time; results suggest predictive capacity potentially superior to serology, 
making them potentially useful as surrogate biomarkers.
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Chagas disease (CD), caused by the protozoan parasite 
Trypanosoma cruzi, is the most neglected tropical disease in 
Latin America [1, 2]. It is estimated that 8 million people are 
infected worldwide [3]. Vector-mediated transmission by tri-
atomine bugs occurs in rural and suburban areas in Central 
and South America. In nonendemic countries, CD is no longer 
an exotic disease but has become an increasing public health 
concern [4]. This is the result of population migration, verti-
cal transmission, organ transplantation, and blood transfusion, 
resulting in a high percentage of chronic asymptomatic patients 
in these populations [2, 5, 6].
Currently, there are no reliable tests or validated biomarkers 
to ensure parasitological cure in chronically infected patients. 
Polymerase chain reaction (PCR) techniques lack sensitivity 
when parasitemia is low and do not guarantee parasitologi-
cal cure [7, 8]. Serological tests cannot discriminate between 
treated individuals and those with CD and have shown incon-
sistent results in adult studies [9]. Blood bank evaluations rely 
on serological testing, and confirmation assays must be per-
formed to elucidate the status of non-negative results [10, 11]. 
In addition, seroreversion, the gold standard, can take decades 
in adults. This is a major barrier to determining the optimal 
treatment duration for currently available drugs or the assess-
ment of potential new drugs in proof-of-concept clinical trials 
[12–15]. Clearly, there is an urgent need for reliable biomarkers 
[12, 13].
Of all the parasite biomarkers proposed over the last decade 
(reviewed in [13, 14, 16]), very few, if any, have been validated 
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and can be used to determine treatment efficacy. Using a pro-
teomic platform to compare serum protein profiles of asymp-
tomatic chronically infected CD patients and healthy controls, 
we identified different host biomarkers [17]. Candidate bio-
markers were further evaluated in a cohort of adult patients 
treated with nifurtimox (Nfx) and followed up for 3 years [18]. 
Among these, the most promising candidates were apolipo-
protein A-I (ApoA1) and fibronectin (FBN) fragments, which 
were significantly upregulated in chronic or asymptomatic CD 
subjects compared with healthy controls (HCs) and returned to 
levels similar to those seen in HCs 3 years after Nfx treatment. 
Immunoblot assays for some of these proteomics-derived bio-
markers were successfully developed and used to assess parasi-
tological cure after Nfx treatment [18].
Our unexpected discovery prompted us to study T. cruzi–host 
interactions further. Indeed, several lines of evidence suggest 
that T.  cruzi can take up low-density lipoprotein (LDL) parti-
cles, can be found in adipose tissue (a potential reservoir site of 
the parasite in man), and use LDL receptors during cell inva-
sion, which leads to the increased accumulation of LDL chol-
esterol in host tissue in both acute and chronic CD [19–23]. In 
addition, truncated forms of ApoA1 have been shown to result 
from the digestion of native ApoA1 in high-density lipoproteins 
(HDLs) by cruzipain, a T. cruzi cysteine protease, in vitro and 
in vivo [24, 25]. Computational studies suggest that n-terminal 
and c-terminal ApoA1 peptides are important for its lipid asso-
ciation to form HDL particles [26]; however, the effect of ApoA1 
truncations in HDL metabolism remains to be studied.
These findings suggest that ApoA1 fragments, among others, 
could be valid indicators of parasite signature and promising 
biomarkers to assess cure in Chagas patients. Taking advantage 
of the more rapid seroreversion in children (a few months to a 
few years), we investigated if the absence and/or reduction of 
ApoA1 and FBN fragments correlated with seroreversion in a 
cohort of children treated with benznidazole (BZ) and followed 
until seroreversion. This correlation, which has been impossi-
ble in adult samples, confirmed these fragments as signatures 




The protocol of this study was approved by the Ethical Boards 
for Medical Research of the Hospital de Niños Ricardo 
Gutierrez, Buenos Aires, Argentina (approval number CEI 
14/14, institutional ethical committee). Written consent was 
required from patients’ legal representatives and was obtained 
from all patients or legal guardians, as appropriate.
Study Design and Setting
The cohort study took place at the Hospital de Niños 
R.  Gutierrez. The study included children between 1  month 
and 10 years old, born in Argentina, mainly infected by ver-
tical transmission, and whose mothers were from Argentina, 
Bolivia, or Paraguay and were not treated before or during 
pregnancy. CD children <6  months were diagnosed by posi-
tive T. cruzi parasitemia (microhematocrit and PCR), serolog-
ical tests (enzyme-linked immunosorbent assay [ELISA] and 
indirect hemagglutination antibody test [IHA]; Wiener Lab, 
Rosario, Argentina). Older children were diagnosed only by 
serological tests. PCR was performed as described by Duffy 
et  al. [27]; serological tests were chosen for diagnosis and 
prognosis following Argentinian guidelines. CD children were 
treated with 5–8 mg/kg/d BZ for 60 days. BZ treatment effi-
cacy in infants younger than 8 months was evaluated by par-
asitemia (microhematocrit and/or PCR) and serology at the 
end of BZ treatment. Older children were evaluated by PCR 
and serology. All children were followed up and evaluated by 
serology every 3 months during the first year post-treatment 
and then every 6  months until 2 consecutive negative sero-
logical results. Children were considered cured when at least 
2 serological tests were negative, as recommended by the 
World Health Organization (WHO). For the proposes of this 
study, only children who reached seroreversion were included. 
Cardiac involvement due to CD was determined by electrocar-
diogram (ECG) and echocardiogram at diagnosis and every 
year after treatment. Thirty children within the same age range 
were used as healthy negative controls for serology, mass spec-
trometry analysis, and immunoblot. Samples from 10 infected, 
untreated mothers and 15 uninfected adults were evaluated 
using the same serological tests and included as positive con-
trols and negative controls for immunoblots, respectively.
Sample Collection
Serum samples were collected in tubes without anticoagulant, 
centrifuged, and aliquoted for serological tests, immunoblot 
assay, and proteomics analysis. All samples were stored at –20°C 
within 1 hour of collection. Aliquots for each subject at diagnosis 
(S0), end of BZ treatment (S1), and seroreversion (S2) were sent 
to the National Reference Center for Parasitology (Montreal, 
Quebec) for immunoblotting and proteomics analysis.
Immunoblot Analysis
Rabbit antisera against the predicted neo-termini of a 24.7-KDa 
ApoA1 fragment and a 28.9-KDa fibronectin fragment were 
generated and used in immunoblots as described by Santamaria 
et  al. [18]. Briefly, 1-μL serum samples were separated in 
4%–12% Novex Bis-Tris Midi gradient gels (Life Technologies, 
Carlsbad, CA) under reducing conditions and transferred onto 
nitrocellulose membranes. Membranes were blocked in 5% 
milk-0.05% Tween-20 in phosphate buffer saline and incubated 
overnight at 4°C with rabbit anti-ApoA1 (24.7) 1:500 or rabbit 
anti-FBN (28) 1:1000 dilution. Then, they were incubated for 
1 hour at room temperature with horseradish peroxidase-con-
jugated antirabbit IgG (GE Healthcare Life Sciences, Uppsala, 
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Sweden) 1:100 000 dilution. Bands were developed by chemilu-
minescence using SuperSignal West Pico (Pierce, Rockford, IL) 
and exposed to x-ray film. Antibody specificity to new n-ter-
mini fragments was demonstrated by the detection of recom-
binant proteins of the respective fragments and the absence of 
detection of full-length proteins.
Serum Fractionation and Profiling
High-throughput serum fractionation by ion exchange chro-
matography was performed using a ProteinChip serum frac-
tionation kit (Bio-Rad, Hercules, CA) as described by Ndao 
et al. [17]. All transfers and incubations were performed in an 
automatized liquid handling station (Biomek FX, Beckman-
Coulter, Brea, CA). Our previous studies [17, 18] show that 
biomarkers of 28.9 and 24.7 KDa were present in fractions 1 
(pH 9) and 3 (pH 5), respectively. These fractions were further 
analyzed using liquid chromatography–mass spectrometry 
(LC-MS).
Serum fractions were desalted, dried, and reconstituted in 
30  µL of water–0.1% formic acid (FA) for mass spectrometry 
intact proteins analysis using a Maxis ESI/Q-TOF mass spec-
trometer (Bruker, Bellirica, MA) coupled with uHPLC (Dionex 
Ultimate 3000 RSLC nano-HPLC, Thermo Fisher Scientific, 
Waltham, MA). In brief, 5 µL of each fraction was loaded onto 
a C4 analytical column (5 µm–300 Å, 150*1 mm; Phenomenex, 
Torrance, CA). Proteins were separated on a linear gradient of 
5%–90% of solvent B at a flow rate of 175 µL/min. Solvent A was 
water–0.1% FA, and solvent B was acetonitrile–0.8% FA.
Continuous mass spectra during the chromatogram run were 
acquired in MS mode between 400 and 3000 m/z. Scan speed 
was set at 1 Hz and ESI at 4200 V – N2 7l/min – 220°C. Data 
files were analyzed using Compass Data Analysis 4.3 Software 
(Bruker, Bellirica, MA). Profiles from CD and HC children were 
compared using Bruker Compass Profile Analysis 2.1 software 
(Bruker, Bellirica, MA). An ANOVA t test model and a princi-
pal component analysis model were generated to identify peaks 
significantly different between HC and CD groups. Maximum 
entropy deconvolution was used to calculate protein peak 
masses for the biomarkers of 24.7 and 28.9 KDa discovered in 
our previous studies [17, 18].
ApoA1 Full-Length Identification by LC–Tandem MS 
To establish the ApoA1 full-length identity in HCs, precursor 
ions for masses similar to full-length ApoA1 were submitted 
for a second analysis using a tandem mass spectrometry (MS/
MS) acquisition method. MS/MS spectra were submitted to 
Bruker Daltonics BioTools 3.2 SR4 software (Bruker, Bellirica, 
MA) for protein identification using the Mascot Search Engine 
server, version 2.2.4 (Matrix Science, London, UK). Spectra 
were searched against human databases (Uniprot) with the fol-
lowing parameters: top-down analysis, no enzymatic digestion, 




All CD patients were asymptomatic with no cardiac involve-
ment or other Chagas-associated pathology at enrollment. BZ 
treatment was well tolerated with mild adverse events [28]. 
Table 1 shows the sociodemographic and clinical characteristics 
of the 60 children included in the study. The parasitology and 
serology results at diagnosis (S0), end of BZ treatment (S1), and 
seroreversion (S2) are summarized in Supplementary Table 1. 
All children included in the study showed negative parasitemia 
by microhematocrit and/or PCR at S1 and remained negative 
until S2. ELISA and IHA titers were reduced or negative at S1 
compared with S0 (Supplementary Table 1); titers continued to 
decrease until S2. Serological test results showed discrepancies 
(Supplementary Table 1), as observed in other studies [9, 10]; 
thus, children were only considered cured when at least 2 tests 
were negative, as recommended by the WHO.
Immunoblot of 24.7-KDa ApoA1 and 28.9-KDa FBN Fragments in Sera
ApoA1 and FBN digestion by cruzipain generates new 
N-termini fragments. Accordingly, antibodies against 
neo-peptides will recognize the protein fragments but not 
their full lengths, even if they are polyclonal antibodies; this 
specificity is demonstrated in Figure  1. When comparing 
infected (CD child) and noninfected samples (HC child and 
HC adult), the antisera selectively detected ApoA1 (24.7) 
(Figure  1A) and FBN (28.9) (Figure  1B) fragments in sam-
ples from CD children, whereas no band corresponding to 
the sizes of the fragments or full-length proteins was detected 
in HC children and adults, supporting previous observations 
[18]. Additionally, antibodies recognized specifically the 
Table 1. Sociodemographic and Clinical Characteristics of 30 CD Child 
Patients and 30 HC Children
CD children HC children
Age at diagnosis 1 mo 7 None
2–11 mo 11 15
>1 y 12 15
Sex Female 15 15
Male 15 15
Origin Buenos Aires 22 N/A
Entre Rios 1
Capital Federal 7
Infection route Congenital 28
Unknown 2









Abbreviations: CD, Chagas disease; HC, healthy control.
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corresponding fragments in infected mothers (Supplementary 
Figure 1) and did not show reactivity with any of the HC chil-
dren and adults (not shown).
Using the immunoblot described above, ApoA1 and 
FBN fragments were undetected at S2 in all (30 of 30 sam-
ples; 100%) and 29 of 30 (96.6%) CD children, respectively. 
However, the only specimen (child of 9.9 years) that was FBN 
positive was very faint. Interestingly, ApoA1 and FBN frag-
ments were undetected by immunoblot at S1 in 20 children 
(66.6%) and 16 children (53.3%), respectively (Figure 2), who 
remained seropositive at this point. In some children, the 
band intensity of fragments at S1 was reduced as compared 
with S0 (children of 4 months for ApoA1 and 10 months for 
FBN) (Figure 2).
Profiling Analysis of Serum Proteins
To confirm the immunoblot results and further emphasize the 
potential of ApoA1 24.7-KDa and FBN 28.9-KDa fragments as 
biomarkers of cure for CD, serum protein profiles were deter-
mined by mass spectrometry. Additionally, we searched for 
proteins corresponding to full-length ApoA1 in CD and HC 
children. Upon MS data analysis, proteins of around 28 KDa 
were detected at 38.5 minutes of the liquid chromatography 















































Figure 1. Immunoblot analysis of ApoA1 (24.7) and FBN (28.9) fragments in CD and HC. Each antiserum detects expected bands in a CD child but not in child or adult 
HCs. The specificity of the rabbit anti-ApoA1 (24.7) serum (A) and rabbit anti-FBN (28) (B) for the corresponding fragments is demonstrated by their inability to detect native 
full-length proteins, ApoA1 (~28.1 KDa) and FBN (~220 KDa), while reacting with 6xHis tag recombinants of the 24.7-KDa ApoA1 and 28.9-KDa FBN (migration at ~35 KDa) 































Figure 2. Immunoblot analysis of apolipoprotein A-1 (24.7) and fibronectin (28.9) fragments in serum samples from Chagas disease (CD) children at different time points. 
Serum from CD children age >1 year and younger were collected at diagnosis (S0), end of treatment (S1), and at seronegative conversion (S2). Immunoblot analysis was 
performed on 1 uL of serum using polyclonal antibodies against neo-peptides PALEDL and PFTDV from APOA1 24.7-KDa and FBN 28.9-KDa fragments, respectively.
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a mass of 28 109 Da, was present in the extracted ion chromato-
gram of HCs and statistically upregulated in HCs compared 
with CD patients (P = .03617) (Figure 3A). A second MS acqui-
sition for the precursor ion in HC confirmed that the protein 
corresponds to full-length ApoA1 (Figure 3B).
CD and HC serum fractions 1 and 3 were analyzed by MS 
and searched for peaks corresponding to the molecular weight 
of ApoA1 and FBN fragments. Peaks were present in CD 
samples but undetected in HC at the same retention times 
(Supplementary Figure  2), which strongly suggests that these 
fragments are upregulated in CD and correspond to the ApoA1 
and FBN fragments that were identified in our previous studies 
[17, 18].
The same peaks were searched for in serum fractions of CD 
children at the different time points in the study. For this, the 
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Figure 3. A, Volcano plot for all proteins identified in serum sasmples of Chagas disease (CD) and healthy control (HC) children. Mass of 28 109 Da, eluted at 38.5 minutes 
of the liquid chromatography gradient, (red point) is significatively upregulated in HC compared with CD. B, Tandem mass spectrometry spectra of 28 109 Da mass precursor 
peak and Biotools results that confirm the apolipoprotein A-1 identity.
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results. As observed in Figure  4, the masses corresponding 
to the ApoA1 fragment (24 756  Da) and the FBN fragment 
(28 786 Da) were undetected at S2, whereas the mass corre-
sponding to full-length ApoA1 (28 093 Da) was detected. As 
was observed by immunoblot, the detection of the ApoA1 
24.7-KDa mass was reduced at S1 compared with its inten-
sity at S0 (Figure 4A). In contrast, the intensity of full-length 
ApoA1 increases at S1 and S2 compared with its intensity 
at S0 (Figures  4 and 5). The fragments were undetected by 
MS in serum samples that were immunoblot negative at S1 
(Figure 5).
DISCUSSION
Confirmation of parasitological cure during the chronic stage 
of Chagas disease is still challenging. Current diagnostic tools 
have limitations, can lead to inconsistent results, and cannot 
measure cure rates without decades of follow-up [29–31]. This 
lack of suitable tests of parasitological cure and treatment effi-
cacy assessment is the biggest challenge in CD prognosis and 
drug research and development.
In our last 2 cohort studies [17, 18], we presented the first 
proteomic approach to identifying diagnostic biomarkers for 
Chagas disease using top-down proteomics. We demonstrated 
that highly sensitive and specific host biological markers were 
able to distinguish asymptomatic CD adult patients from HC in 
2 different populations [17, 18]. ApoA1 fragments of 24.7, 13.6, 
and 9.1 KDa, as well as a 28.9-KDa FBN fragment, were upreg-
ulated in asymptomatic CD adults and returned to levels similar 
to those seen in HCs after 3 years of Nfx treatment. However, all 
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A
Figure 4. Representative mass spectrometry spectra of biomarkers 24.7 (A) and 28.9 (B) for samples from Chagas children patients treated with benznidazole. Proteins of 
24 756 and 28 786 Da are present at diagnosis (S0), the intensity of 24 756 Da is reduced after treatment (S1), and both biomarkers are no longer detected at seroreversion 
(S2). A peak of 28 078 Da corresponding to apolipoprotein A-1 (~28.1 KDa) is detected at seroreversion.
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possible to compare our biomarker results with seroreversion, 
which is currently the gold standard of parasitological cure.
In the current study, taking advantage of the quicker serolog-
ical conversion in children compared with adults, we collected 
serum samples of CD children at diagnosis, end of BZ treat-
ment, and seroreversion. BZ treatment is well tolerated in chil-
dren [28], and in the present study, all children were followed 
periodically after treatment until 2 serological tests were nega-
tive. This was the perfect scenario for comparing the presence or 
absence of previously identified biomarkers with seroreversion 
and validating their use as biomarkers of parasitological cure.
Using both immunoblot and MS, we observed that ApoA1 
(24.7-KDa) and FBN (28.9-KDa) fragments were present in 
Argentinian CD children, but not in HCs. MS analysis also 
showed that full-length ApoA1 protein was statistically upreg-
ulated in HC children and its abundance increased in serum 
from CD children after treatment and at seroreversion. This 
pattern is consistent with those seen in our previous studies 
with Bolivian and Venezuelan samples [17, 19], which demon-
strates the reproducibility of our approach across the South 
American population, an important factor considering the 
variety of infective T. cruzi strains in patients in these regions. 
This reproducibility was also achieved using different proteom-
ics platforms, reinforcing the robustness of our data.
These fragments were absent in samples from CD children 
treated with BZ and considered cured as determined by seror-
eversion. To our knowledge, this is the first time that a correl-
ation has been established between the presence/absence of a 
newly identified marker and seroconversion in Chagas disease. 
Potential CD biomarkers have been studied in CD children 
during the early chronic indeterminate stage. Soluble platelet 
selectin (sP-selectin) and soluble vascular cell adhesion mole-
cule–1 (sVCAM-1) titers decreased in 66.7% and 41% of the 
children treated with BZ compared with controls [32]. Equally, 
interferon-γ profiles and M2 muscarinic receptor autoantibody 
(anti-M2R AAb) were decreased 6 months after BZ treatment. 
Anti-M2R AAb reactivity declined to between 29.7% and 88.1% 
of the initial level [33]. Specific cellular surface markers associ-
ated with a type 1–modulated cytokine pattern were elevated 
after BZ treatment in a different study [33]. However, none of 
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Figure 5. Mass spectrometry spectra of biomarkers 24.7 (A) and 28.9 (B) for children’s samples that show negative immunoblot results at the end of benznidazole (BZ) 
treatment (S1). Proteins of 24 758 and 28 803 Da are present at diagnosis (S0) but are undetected at the end of BZ treatment (S1) and seroconversion (S2); instead, proteins 
corresponding to full-length apolipoprotein A-1 (~28.1 KDa) are detected at S1 and S2.
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Interestingly, the ApoA1 (24.7-KDa) and FBN (28.9-KDa) 
fragments were absent at the end of BZ treatment in 66.6% and 
53.3% of the total child population, respectively, even though 
the children remained seropositive at this time point. This sug-
gests that these biomarkers could predict parasitological cure 
earlier than conventional tests or that some children might not 
require a full 60 days of BZ treatment. Additional studies are 
needed to continue the validation of these new biomarkers; in 
particular, the kinetics of the disappearance of the fragments 
following treatment needs to be further evaluated. Serum sam-
ples collected at different time points during treatment, as well 
as between treatment and seroreversion, should give us a better 
idea of their potential to determine cure earlier than conven-
tional serology.
Moreover, a test or multiplex allowing the testing of more 
samples from adults and children at a higher throughput is 
needed before moving toward clinical use of ApoA1 and FBN 
fragments as biomarkers of parasitological cure for Chagas 
disease.
Overall, our data strongly suggest that ApoA1 and FBN 
fragments, together with ApoA1 full-length protein, are valid 
markers to be considered for discriminating infected from 
uninfected samples in clinical settings, and for the assessment 
of treatment efficacy in Chagas patients. Immunoblot results 
matched the detection of fragments by MS, which suggests that 
the immunoblot assay derived from our proteomics studies is 
good enough to evaluate CD patients and determine parasito-
logical cure. This is a successful translation of proteomic-based 
studies into accessible tools for bench diagnosis.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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